Katsuhiro Hayashi
Overview
Explore the profile of Katsuhiro Hayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
316
Citations
3165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Morinaga S, Han Q, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
In Vivo
. 2024 Dec;
39(1):120-126.
PMID: 39740911
Background/aim: Ifosfamide is used clinically with doxorubicin as first-line chemotherapy for soft-tissue sarcoma. However, ifosfamide efficacy for soft-tissue sarcoma is limited due to frequent occurence of ifosfamide resistance and thus...
12.
Morinaga S, Zhao M, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
In Vivo
. 2024 Dec;
39(1):102-109.
PMID: 39740880
Background/aim: Salmonella typhimurium A1-R (A1-R) targets and inhibits a wide range of cancer types without continuously infecting healthy tissue. Chloroquine, an antimalarial drug, induces apoptosis and inhibits autophagy in cancer...
13.
Morinaga S, Han Q, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
Anticancer Res
. 2024 Dec;
45(1):97-103.
PMID: 39740811
Background/aim: Ivermectin was initially utilized as a veterinary medication, demonstrating efficacy against various parasites. Pancreatic cancer is currently one of the most recalcitrant diseases. The aim of the present study...
14.
Morinaga S, Han Q, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
Anticancer Res
. 2024 Dec;
44(12):5207-5213.
PMID: 39626920
Background/aim: Docetaxel combined with gemcitabine is a second-line treatment for soft-tissue sarcoma; however, its effectiveness is limited because of docetaxel resistance. The objective of the present study was to determine...
15.
Araki Y, Hirose K, Hirose M, Hayashi K, Demura S
Medicine (Baltimore)
. 2024 Nov;
103(44):e40344.
PMID: 39495994
Rationale: As the elderly population grows, the number of joint arthroplasty surgeries is also increasing. Periprosthetic joint infection (PJI) is a postoperative complication that occurs in 1%-2% of the arthroplasties....
16.
Morinaga S, Zhao M, Mizuta K, Kang B, Sato M, Bouvet M, et al.
In Vivo
. 2024 Oct;
38(6):2601-2609.
PMID: 39477429
Background/aim: Salmonella typhimurium A1-R has been shown to target and inhibit many types of cancers in mouse models without continuous infection of normal tissue. The objective of the present study...
17.
Morinaga S, Han Q, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
Anticancer Res
. 2024 Oct;
44(11):4773-4778.
PMID: 39477291
Background/aim: Docetaxel combined with gemcitabine is a second-line therapy for osteosarcoma, but its efficacy is limited by the development of docetaxel resistance. The aim of the present study was to...
18.
Morinaga S, Han Q, Mizuta K, Kang B, Sato M, Bouvet M, et al.
Cancer Genomics Proteomics
. 2024 Oct;
21(6):585-590.
PMID: 39467627
Background/aim: Methionine restriction selectively arrests cancer cells during the S-phase of the cell cycle. We hypothesized that DNA damage may occur in S-phase in cancer cells during methionine restriction. To...
19.
Asano Y, Yamamoto N, Hayashi K, Takeuchi A, Kato S, Miwa S, et al.
Anticancer Res
. 2024 Sep;
44(10):4493-4503.
PMID: 39348990
Background/aim: The aim of the study was to develop a novel predictive scoring system based on the dynamics of serum inflammatory indicators in immune checkpoint inhibitor (ICI) treatment on non-small-cell...
20.
Morinaga S, Yamamoto N, Yamauchi K, Hayashi K, Kimura H, Miwa S, et al.
Cancer Diagn Progn
. 2024 Sep;
4(5):544-557.
PMID: 39238629
The field of experimental microsurgery was pioneered by the great microsurgeon Sun Lee, who developed the foundation of transplant surgery in the clinic. Dr Lee also played a seminal role...